Isomorphic Labs, Google’s A.I. drug division, has raised $600 million, led by Thrive Capital. This funding highlights their advancements in drug design using A.I., particularly with technologies like AlphaFold, which accelerates drug development. The company aims to transform the drug discovery process through computerization.
Isomorphic Labs, Google’s ambitious A.I. drug division, has secured an impressive $600 million in funding, led by Thrive Capital. This funding marks a significant stride in their mission to revolutionize drug development through cutting-edge artificial intelligence. Thrive Capital, known for its investments in leading A.I. companies like OpenAI, joins the financial backing of Google’s own venture arm, GV, and parent company Alphabet.
Over the past year, Isomorphic Labs has made remarkable progress in drug design, thanks to innovative advancements in mimicking human biology. Their software, a byproduct of DeepMind’s advanced research, includes technologies like AlphaFold. This tool is capable of predicting protein structures and has significantly expedited the drug development timeline, demonstrating a glimpse into the future of pharmaceutical science.
AlphaFold’s third iteration offers profound insights into DNA and RNA behavior, enhancing its ability to streamline drug discovery processes. The technology’s potential has already garnered recognition, as key figures from Isomorphic and DeepMind, Demis Hassabis and John M. Jumper, jointly received a Nobel Prize in Chemistry last year. Their vision, as articulated by Hassabis, centers on transforming early-stage drug research to be largely executed by computers, minimizing reliance on conventional lab settings.
The $600 million funding for Isomorphic Labs accentuates Google’s commitment to pioneering A.I. in drug discovery. With breakthrough technologies like AlphaFold, the company is reshaping the future of pharmaceutical development, moving towards a computer-driven approach that promises efficiency and innovation. This funding will play a pivotal role in propelling Isomorphic Labs towards achieving its ambitious goals.
Original Source: www.nytimes.com
